Compare DNUT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | RGNX |
|---|---|---|
| Founded | 1937 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.4M | 761.9M |
| IPO Year | 2021 | 2015 |
| Metric | DNUT | RGNX |
|---|---|---|
| Price | $3.65 | $13.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $6.22 | ★ $30.78 |
| AVG Volume (30 Days) | ★ 2.4M | 696.9K |
| Earning Date | 02-24-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,534,272,000.00 | $161,318,000.00 |
| Revenue This Year | N/A | $133.58 |
| Revenue Next Year | $0.19 | $45.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $2.50 | $5.04 |
| 52 Week High | $9.56 | $15.84 |
| Indicator | DNUT | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 34.87 | 46.45 |
| Support Level | $4.12 | $14.53 |
| Resistance Level | $4.49 | $15.31 |
| Average True Range (ATR) | 0.22 | 0.89 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 3.30 | 24.58 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.